• 1119 Citations
  • 15 h-Index
19962019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Zhongsheng Tong is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Triple Negative Breast Neoplasms Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1996 2019

  • 1119 Citations
  • 15 h-Index
  • 113 Article
  • 10 Review article
  • 1 Short survey

Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer

Jia, Y., Song, Y., Dong, G., Hao, C., Zhao, W., Li, S. & Tong, Z., Dec 1 2019, In : Scientific reports. 9, 1, 12939.

Research output: Contribution to journalArticle

Open Access
Neoadjuvant Therapy
Estrogen Receptors
Breast Neoplasms
Aromatase Inhibitors
Neoplasm Genes
1 Citation (Scopus)

ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF-κB activation

Jin, X. H., Jia, Y. S., Shi, Y. H., Li, Q. Y., Bao, S. Q., Lu, W. P. & Tong, Z., Feb 1 2019, In : Journal of cellular biochemistry. 120, 2, p. 1386-1397 12 p.

Research output: Contribution to journalArticle

Tamoxifen
Chemical activation
Cells
Breast Neoplasms
Cell Line
1 Citation (Scopus)

Microcalcification and BMP-2 in breast cancer: Correlation with clinicopathological features and outcomes

Zhang, L., Hao, C., Wu, Y., Zhu, Y., Ren, Y. & Tong, Z., Jan 1 2019, In : OncoTargets and Therapy. 12, p. 2023-2033 11 p.

Research output: Contribution to journalArticle

Open Access
Calcinosis
Breast Neoplasms
Control Groups
Ductal Carcinoma
Carcinoma, Intraductal, Noninfiltrating
3 Citations (Scopus)

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., Tong, Z., Cheng, Y., Pan, Y., Sun, Y., Wang, H., Ouyang, T., Gu, K., Feng, J., Wang, X., Wang, S. & 5 others, Liu, T., Gao, J., Cristofanilli, M., Ning, Z. & Lu, X., Jun 1 2019, In : The lancet oncology. 20, 6, p. 806-815 10 p.

Research output: Contribution to journalArticle

exemestane
Placebos
Hormones
Breast Neoplasms
Random Allocation

乳腺癌内分泌治疗耐药机制的研究进展

Translated title of the contribution: Research advances in mechanisms of endocrine therapy resistance for breast cancerJia, Y. & Tong, Z., Jan 1 2019, In : Chinese Journal of Clinical Oncology. 46, 4, p. 204-207 4 p.

Research output: Contribution to journalArticle

Estrogen Receptors
Breast Neoplasms
Research
Therapeutics
Therapeutic Uses